Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
La radiologia medica
Published in: La radiologia medica 4/2014

01-04-2014 | Abdominal Radiology

Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results

Authors: Giuseppe Salvaggio, Alessandro Furlan, Francesco Agnello, Giuseppe Cabibbo, Daniele Marin, Lydia Giannitrapani, Chiara Genco, Massimo Midiri, Roberto Lagalla, Giuseppe Brancatelli

Published in: La radiologia medica | Issue 4/2014

Login to get access

Abstract

Purpose

This study was undertaken to compare response evaluation criteria in solid tumours (RECIST) 1.1 and modified RECIST (mRECIST) in patients with unresectable hepatocellular carcinoma (HCC) on sorafenib, and to describe HCC enhancement changes before and after sorafenib treatment.

Methods and materials

Seventeen patients (12 men, 5 women; mean age 69 years; age range 58–79 years) were included. Tumour response was assessed according to RECIST and mRECIST. Two readers placed a region of interest (ROI) within each target lesion, on the portion showing enhancement during the arterial phase. The lesion attenuation values measured within the ROIs on computed tomography or the signal intensity measured on magnetic resonance imaging, during the unenhanced phase, hepatic arterial phase and venous phase were recorded. Changes in arterial and venous contrast enhancement before and after treatment were compared among the mRECIST groups using Mann–Whitney U test.

Results

Agreement between mRECIST and RECIST was good (Cohen’s k coefficient, 0.791). Patients with partial response had a greater decrease in arterial enhancement (−79.8 %) than did patients with stable disease (SD) (−24.8 %; p = 0.011) or progressive disease (PD) (−32.9 %; p = 0.034). No statistically significant difference in arterial enhancement variation was found among patients with SD and PD. No statistically significant difference in venous enhancement was found among the mRECIST groups.

Conclusions

mRECIST showed a more favourable response compared to RECIST 1.1 in patients with unresectable HCC receiving sorafenib.
Literature
1.
Bruix J, Sherman M (2010) Practice Guidelines Committee AASLD. Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRef
2.
3.
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
4.
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMed
5.
Sullivan DC, Gatsonis C (2011) Response to treatment series: part 1 and introduction, measuring tumor response—challenges in the era of molecular medicine. AJR Am J Roentgenol 197:15–17CrossRefPubMed
6.
Faivre S, Zappa M, Vilgrain V et al (2011) Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res 17:4504–4512CrossRefPubMed
7.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
8.
Maksimovic O, Schraml C, Hartmann J et al (2010) Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am J Roentgenol 194:5–14CrossRefPubMed
9.
Edeline J, Boucher E, Rolland Y et al (2012) Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 118:147–156CrossRefPubMed
10.
Smith AD, Lieber ML, Shah SN (2010) Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 194:157–165CrossRefPubMed
11.
Yaghmai V, Miller FH, Rezai P et al (2011) Response to treatment series: part 2, tumor response assessment—using new and conventional criteria. AJR Am J Roentgenol 197:18–27CrossRefPubMed
12.
Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60CrossRefPubMed
13.
Horger M, Lauer UM, Schraml C et al (2009) Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 28:208CrossRef
14.
Spira D, Fenchel M, Lauer UM et al (2011) Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 18:89–96CrossRefPubMed
15.
Kim KW, Lee JM, Choi BI (2011) Assessment of the treatment response of HCC. Abdom Imaging 36:300–314CrossRefPubMed
16.
Choi H, Charnsangavej C, de Castro Faria S et al (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183:1619–1628CrossRefPubMed
17.
Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759CrossRefPubMed
18.
Jiang T, Kambadakone A, Kulkarni NM et al (2012) Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 47:11–17CrossRefPubMed
19.
Sabir A, Schor-Bardach R, Wilcox CJ et al (2008) Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 191:133–139CrossRefPubMed
20.
Wang J, Chen LT, Tsang YM et al (2004) Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 183:713–719CrossRefPubMed
Metadata
Title
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results
Authors
Giuseppe Salvaggio
Alessandro Furlan
Francesco Agnello
Giuseppe Cabibbo
Daniele Marin
Lydia Giannitrapani
Chiara Genco
Massimo Midiri
Roberto Lagalla
Giuseppe Brancatelli
Publication date
01-04-2014
Publisher
Springer Milan
Published in
La radiologia medica / Issue 4/2014
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI
https://doi.org/10.1007/s11547-013-0332-5

Other articles of this Issue 4/2014

La radiologia medica 4/2014 Go to the issue

Abdominal Radiology

Imaging findings of hepatic focal nodular hyperplasia in men and women: are they really different?

Resource Management and Health Economics

PET–CT in oncological patients: analysis of informal care costs in cost–benefit assessment

Chest Radiology

Effective DQE (eDQE) and dose to optimize radiographic technical parameters: a survey of pediatric chest X-ray examinations in Korea

Vascular and Interventional Radiology

Transcatheter embolisation of iatrogenic renal vascular injuries

Breast Radiology

Comparison between different imaging techniques in the evaluation of malignant breast lesions: can 3D ultrasound be useful?

Cardiac Radiology

256-slice CT coronary angiography: in vivo dosimetry and technique optimization